Patents Represented by Attorney Stephen Faciszewski
  • Patent number: 7331930
    Abstract: A biopsy/access tool, comprising an integrated biopsy device and access cannula. The biopsy device is internally guided to a remote anatomical site, and the access cannula is adapted to be guided to the same remote anatomical body site by the biopsy device.
    Type: Grant
    Filed: May 31, 2005
    Date of Patent: February 19, 2008
    Assignee: Movdicé Holding, Inc.
    Inventor: Tom Faciszewski
  • Patent number: 7001342
    Abstract: Method of use for a biopsy/access tool, comprising an integrated biopsy device and access cannula. In this method, the biopsy device is internally guided to a remote anatomical site, and the access cannula is adapted to be guided to the same remote anatomical body site by the biopsy device.
    Type: Grant
    Filed: February 11, 2002
    Date of Patent: February 21, 2006
    Assignee: Movdice Holding, Inc.
    Inventor: Tom Faciszewski
  • Patent number: 6136964
    Abstract: There is disclosed cDNA sequences and polypeptides having the enzyme lysophosphatidic acid acyltransferase (LPAAT) activity. LPAAT is also known as 1-acyl sn-glycerol-3-phosphate acyltransferase.
    Type: Grant
    Filed: March 19, 1996
    Date of Patent: October 24, 2000
    Assignee: Cell Therapeutics, Inc.
    Inventors: David W. Leung, James W. West, Christopher K. Tompkins
  • Patent number: 6057328
    Abstract: Disclosed are methods for treating conditions resulting from hyperoxia or mechanical ventilation comprising the administration of a compound of the formula: ##STR1## wherein R.sub.1 is a substantially pure resolved R enantiomer .omega.-1, secondary alcohol-substituted (C.sub.5-8) alkyl; and R.sub.2 and R.sub.3 are independently hydrogen atom or a (C.sub.1-12) alkyl optionally containing one or two oxygen atoms in place of non-adjacent carbon atoms.
    Type: Grant
    Filed: December 31, 1997
    Date of Patent: May 2, 2000
    Assignee: Cell Therapeutics, Inc.
    Inventors: Jack W. Singer, Edward Abraham
  • Patent number: 5955624
    Abstract: Alk-1-enyl glycerol derivatives and method of preparing same. The derivatives stimulate cell and tissue growth.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 21, 1999
    Assignee: Cell Therapeutics, Inc.
    Inventors: Edward Nudelman, Sen-Itiroh Hakomori
  • Patent number: 5952480
    Abstract: There is disclosed cDNA sequences and polypeptides having the enzyme CDP-diacylglycerol synthase (CDS) activity. CDS is also known as CTP:phosphatidate cytidylytransferase. There is further disclosed methods for isolation and production of polypeptides involved in phosphatidic acid metabolism and signaling in mammalian cells, in particular, the production of purified forms of CDS.
    Type: Grant
    Filed: June 28, 1996
    Date of Patent: September 14, 1999
    Assignee: Cell Therapeutics, Inc.
    Inventors: David W. Leung, Reitha Weeks
  • Patent number: 5929081
    Abstract: There is disclosed a method for:(1) inhibiting new blood vessel formation that is useful for treating or preventing progression of diabetic retinopathy, cavernous haemangiomas, Kaposi's sarcoma, tumors composed of endothelial-like cells, and growth of cancer cells by preventing their development of a new blood supply:(2) suppressing development of kidney diseases due to cytokine induced proliferation of mesangial cells and/or glomerular epithelial cells that is useful for treating or preventing progression of diabetic glomerulosclerosis and other glomerulonephritides of various types and etiologies;(3) preventing joint destruction accompanying rheumatoid arthritis due to proliferation of synovial cells;(4) suppressing manifestations of psoriasis due to proliferation of keratinocytes and accumulation of inflammatory cells;(5) suppressing accelerated atherogenesis involved in restenosis of coronary vessels or other arterial vessels following angioplasty;(6) suppressing atherogenesis, coronary artery disease and
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 27, 1999
    Assignee: Cell Therapeutics Inc.
    Inventors: Paul A. Brown, Stuart L. Bursten, Glenn C. Rice, Jack W. Singer
  • Patent number: 5859017
    Abstract: In a method for treating or preventing allergy or allergic disorders an effective amount of a compound that inhibits intracellular generation of phosphatidic acid and diacylglycerol is administered. The intracellular generation of phosphatidic acid and diacylglycerol results from allergen presentation or mast cell/basophil activation.
    Type: Grant
    Filed: April 1, 1994
    Date of Patent: January 12, 1999
    Assignee: Cell Therapeutics, Inc.
    Inventors: Elisa Eiseman, Emer Clarke, Jack W. Singer, Stuart L. Bursten
  • Patent number: 5859018
    Abstract: There is disclosed a method for:(1) inhibiting new blood vessel formation that is useful for treating or preventing progression of diabetic retinopathy, cavernous haemangiomas, Kaposi's sarcoma, tumors composed of endothelial-like cells, and growth of cancer cells by preventing their development of a new blood supply:(2) suppressing development of kidney diseases due to cytokine induced proliferation of mesangial cells and/or glomerular epithelial cells that is useful for treating or preventing progression of diabetic glomerulosclerosis and other glomerulonephritides of various types and etiologies;(3) preventing joint destruction accompanying rheumatoid arthritis due to proliferation of synovial cells;(4) suppressing manifestations of psoriasis due to proliferation of keratinocytes and accumulation of inflammatory cells;(5) suppressing accelerated atherogenesis involved in restenosis of coronary vessels or other arterial vessels following angioplasty;(6) suppressing atherogenesis, coronary artery disease and
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 12, 1999
    Assignee: Cell Therapeutics, Inc.
    Inventors: Paul A. Brown, Stuart L. Bursten, Glenn C. Rice, Jack W. Singer
  • Patent number: 5837703
    Abstract: Therapeutic compounds have the formula:(X)j-(core moiety),j being an integer from one to three, the core moiety comprising a core moiety, the core moiety being a heterocycle having one ring or two-fused rings, each ring having five or six ring atoms, A being a carbon atom of the core moiety and attached to a terminal carbon atom of (CH.sub.2).sub.m, and X has a structure and X being a racemic mixture, R or S enantiomer, solvate, hydrate, or salt of: ##STR1## *C is a chiral carbon atom, n is an integer from one to four (preferably from one to three), one or more carbon atoms of (CH.sub.2).sub.n may be substituted by a keto or hydroxy group, and m is an integer from one to fourteen. Independently, R.sub.1 and R.sub.2 may be a hydrogen, a straight or branched chain alkyl or alkenyl of up to twelve carbon atoms in length, or --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.
    Type: Grant
    Filed: November 12, 1993
    Date of Patent: November 17, 1998
    Assignee: Cell Therapeutics, Inc.
    Inventors: Anil M. Kumar, John Michnick, Gail E. Underiner, J. Peter Klein, Glenn C. Rice
  • Patent number: 5798386
    Abstract: There is disclosed an aqueous formulation for vascularizing ischemic or grafted tissue, comprising an alk-1-enyl glycerol derivative having the formula: ##STR1## wherein R is a straight or branched C.sub.1-24 saturated or unsaturated alkyl or a straight or branched C.sub.1-24 aryl and X and Y each is H or an saturated or unsaturated alkyl group having from 2 to 26 carbon atoms, or a monoglyceride having a C.sub.1-24 ether-linked saturated alkyl in an aqueous buffered pharmaceutical carrier.
    Type: Grant
    Filed: March 4, 1996
    Date of Patent: August 25, 1998
    Assignee: Cell Therapeutics, Inc.
    Inventor: Edward D. Nudelman
  • Patent number: 5795897
    Abstract: There is disclosed a pharmaceutical composition comprising 1-(5-oxohexyl)-3-methylxanthine in admixture with a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is useful for treating an immune disorder. There is also disclosed a method to modulate the response of a target cell to a stimulus, which method comprises contacting said cell with an amount of 1-(5-oxohexyl)-3-methylxanthine or a pharmaceutical composition thereof, wherein said amount effects a diminution in elevated levels of unsaturated, non-arachidonate phosphatidic acid (PA) and diacylglycerol (DAG) derived from said PA in said cells wherein said elevated levels are stimulated by an agent capable of elevating levels of said PA and said DAG, said diminution being equal to or greater than the diminution effected by treating said cells with pentoxifylline (PTX) at a concentration of 0.5 mmol, thereby modulating the response of said target cell.
    Type: Grant
    Filed: April 13, 1994
    Date of Patent: August 18, 1998
    Assignee: Cell Therapeutics, Inc.
    Inventor: Gail Underiner
  • Patent number: 5795898
    Abstract: There is disclosed a method for:(1) inhibiting new blood vessel formation that is useful for treating or preventing progression of diabetic retinopathy, cavernous haemangiomas, Kaposi's sarcoma, tumors composed of endothelial-like cells, and growth of cancer cells by preventing their development of a new blood supply:(2) suppressing development of kidney diseases due to cytokine induced proliferation of mesangial cells and/or glomerular epithelial cells that is useful for treating or preventing progression of diabetic glomerulosclerosis and other glomerulonephritides of various types and etiologies;(3) preventing joint destruction accompanying rheumatoid arthritis due to proliferation of synovial cells;(4) suppressing manifestations of psoriasis due to proliferation of keratinocytes and accumulation of inflammatory cells;(5) suppressing accelerated atherogenesis involved in restenosis of coronary vessels or other arterial vessels following angioplasty;(6) suppressing atherogenesis, coronary artery disease and
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 18, 1998
    Assignee: Cell Therapeutics, Inc.
    Inventors: Paul A. Brown, Stuart L. Bursten, Glenn C. Rice, Jack W. Singer
  • Patent number: 5780237
    Abstract: There is disclosed a diagnostic assay for adult respiratory distress syndrome (ARDS), sepsis, multiple organ dysfunction (MOD) and systemic inflammatory response syndrome (SIRS), comprising (a) measuring the amount of selected unsaturated free fatty acids (FFAs) and saturated FFAs in a body fluid, and (b) determining a ratio value comprising the sum of the unsaturated FFAs divided by the sum of the saturated FFAs. There is further disclosed a diagnostic assay for ARDS, sepsis, MOD and SIRS, comprising (a) measuring the amount of 9- or 13-hydroxyoctadecadienoic acid (HODE) and 5-hydroxy-6-trans-8,11,14-cis-eicosatetraenoic acid (5-HETE) in a body fluid, and (b) determining a ratio value of HETE and HODE.
    Type: Grant
    Filed: October 12, 1994
    Date of Patent: July 14, 1998
    Assignee: Cell Therapeutics, Inc.
    Inventors: Stuart L. Bursten, David A. Federighi
  • Patent number: 5773300
    Abstract: There is disclosed a diagnostic assay for determining the presence of a neoplasia or a tumor burden in a mammal comprising (a) measuring the amount of unsaturated free fatty acids (FFAs) linolenate and arachidonate in a body fluid, and (b) determining a ratio value comprising the sum of linolenate and the sum of arachidonate.
    Type: Grant
    Filed: April 23, 1997
    Date of Patent: June 30, 1998
    Assignee: Cell Therapeutics, Inc.
    Inventors: David A. Federighi, Stuart L. Bursten
  • Patent number: 5770595
    Abstract: Oxime-substituted compounds are preferably cyclic or heterocyclic compounds. The oxime-substituted compounds and pharmaceutical compositions thereof have the formula:CORE MOIETY--(R).sub.jincluding resolved enantiomers (both syn and anti forms) and/or diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is non-cyclic or cyclic and R may be selected from among: hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C.sub.(1-10), alkyl, C.sub.(2-10) alkenyl, cyclic or heterocyclic groups, and formula I. At least one R has the formula I:--(CH.sub.2).sub.n --C--(R.sub.1).sub.p, Iwherein n is an integer from three to twenty; p is two or three; R.sub.1 is selected from among hydrogen; halogen; hydroxide; substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxy, C.sub.(2-10) alkenyl, cyclic or heterocyclic group; =N--OR.sub.2, R.sub.2 being hydrogen or a substitute or unsubstituted C.sub.(1-10) alkyl, C.sub.
    Type: Grant
    Filed: February 7, 1994
    Date of Patent: June 23, 1998
    Assignee: Cell Therapeutics, Inc.
    Inventors: J. Peter Klein, Alistair Leigh
  • Patent number: 5756511
    Abstract: A method for treating symptoms of Alzheimer's Disease by administering an effective amount of a compound, racemate, isolated R or S enantionmer, solvate, hydrate or salt having the formula:X--terminal heterocyclic moiety.In the above formula, the terminal heterocyclic moiety is a 3,7-dimethylxanthinyl, 3-methylxanthinyyl or xanthinyl moiety and X is: ##STR1## n is zero or an integer from one to four; and m is an integer from seven to fourteen. For compounds useful in the inventive method, R.sub.1 and R.sub.2 are hydrogen, a straight or branched chain alkyl, alkenyl or alkynyl of up to twenty carbon atoms in length or --(CH.sub.2).sub.w R.sub.5. w may be an integer from one to twenty and R.sub.5 is preferably an hydroxyl, halo C.sub.1-8 alkoxyl group or a substituted or unsubstituted carbocycle or heterocycle. R.sub.3 in compounds useful in the inventive method may be either an hydroxyl group, an oxygen atom, the single bond represented being instead a double bond, or --O--R.sub.4, R.sub.4 being a C.sub.
    Type: Grant
    Filed: April 3, 1995
    Date of Patent: May 26, 1998
    Assignee: Cell Therapeutics, Inc.
    Inventors: James W. West, David W. Leung, J. Peter Klein, Gail E. Underiner, Anil M. Kumar
  • Patent number: 5756453
    Abstract: There is disclosed a method for vascularizing tissue, a method for improving vascularization of ischemic tissue, and a method for improving the viability of grafted tissue or tissue survival in gradient ischemia of heart, brain or skin, comprising administering locally to the grafted or ischemic tissue or the site of the graft an effective amount of a compound comprising an alk-1-enyl glycerol derivative.
    Type: Grant
    Filed: January 31, 1996
    Date of Patent: May 26, 1998
    Assignee: Cell Therapeutics, Inc.
    Inventors: Nicholas B. Vedder, Edward D. Nudelman
  • Patent number: 5739138
    Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: April 14, 1998
    Assignee: Cell Therapeutics, Inc.
    Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
  • Patent number: 5710175
    Abstract: Alk-1-enyl glycerol derivatives and method of preparing same. The derivatives stimulate cell and tissue growth.
    Type: Grant
    Filed: April 4, 1996
    Date of Patent: January 20, 1998
    Assignee: Cell Therapeutics, Inc.
    Inventors: Edward Nudelman, Sen-Itiroh Hakomori